Sharemaestro company-news research for aTyr Pharma, Inc. (ATYR), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest ATYR news and sentiment
aTyr Pharma, Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score49Neutral is 50
Early balanced news score
26/100 evidence confidence
100% direct company focus
32 current stories across 10 publishers
Current company news
Early balanced news score
32 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone46/100
→
Published 30-day score49/100
Latest source headline
aTyr Pharma And 2 Other Penny Stocks With Promising Potential
simplywall.st · 26 Aug 2026 17:24
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
32 current stories are mapped specifically to ATYR.
The score uses 10 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.395.
Confidence is 26/100, below the threshold for a firm score.
49/100
News scoreEarly balanced news score
26/100
Confidencethin evidence
100%/100
Company news32 company stories
77/100
Story agreement23/100 difference
News history
Daily score and story count over 30 days
01 Aug16 Aug30 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence8
0.395 after freshness weightingSource breadth100
10 independent publishersCompany relevance100
share tied directly to this companyFreshness13
recency-weighted evidenceAgreement77
how closely stories agreePublisher mix67
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks24 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
06 Mar02 Jun28 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
28 Aug 202649USD 0.54+7.7%
21 Aug 202646USD 0.5015-10.3%
14 Aug 202644USD 0.559+9.3%
07 Aug 202645USD 0.5114+5.3%
31 Jul 202657USD 0.4857+2.6%
24 Jul 202657USD 0.4733-7.2%
17 Jul 202650USD 0.5098-6.4%
10 Jul 202650USD 0.5444-8.1%
Provisional evidence
News subjects
What is shaping the score
Earnings6219 stories · 59%
Market update505 stories · 16%
Regulatory and legal244 stories · 12%
Analyst action582 stories · 6%
Balance sheet501 stories · 3%
Deals and strategy501 stories · 3%
Source mix
Where the evidence comes from
The National Law Review244 stories · 12%
TradingView414 stories · 12%
vinanet.vn713 stories · 9%
TradingKey503 stories · 9%
simplywall.st502 stories · 6%
Moomoo502 stories · 6%
MarketBeat502 stories · 6%
Recurring subjects
Subjects appearing most often
Life Sciences18Earnings11Finance9Financial Markets6EARNINGS1Clinical Trials1CLINICAL-TRIALS1Biotech1BIOTECH1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
17 Apr50 neutral30 Aug 05:05
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 30 Aug 05:05 | 49 | -1 | 23/100 (-4) | 31 (-5) | Provisional |
| 26 Aug 23:59 | 50 | +0 | 27/100 (-3) | 36 (-2) | Provisional |
| 24 Aug 23:59 | 50 | +5 | 30/100 (-4) | 38 (-6) | Provisional |
| 17 Aug 23:59 | 45 | +1 | 34/100 (-3) | 44 (-2) | Measured |
| 14 Aug 23:59 | 44 | +0 | 37/100 (-3) | 46 (+2) | Measured |
| 12 Aug 23:59 | 44 | +0 | 40/100 (-3) | 44 (+2) | Measured |
| 11 Aug 23:59 | 44 | +0 | 43/100 (-3) | 42 (+1) | Measured |
| 10 Aug 23:59 | 44 | -1 | 46/100 (+1) | 41 (+3) | Measured |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#1—Not directional
simplywall.stDirect company coverageScored from headline
aTyr Pharma And 2 Other Penny Stocks With Promising Potential
- Published
- 26 Aug 2026 17:24
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 2.0d old
- Duplicates
- 1 consolidated
#275Tone
vinanet.vnDirect company coverageScored from headline
aTyr (ATYR) Financial Results: Profit Per Share Surpasses Its Benchmark in the Latest Reading; The Stock Ends Down 0.20% in the Latest Session - EBITDA Margin Trends
- Published
- 24 Aug 2026 05:33
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 64/100
- 30-day weight
- 28.9% of the score · 4.5d old
- Duplicates
- 1 consolidated
#359Tone
Freedom BrokerDirect company coverageStored article
FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III
Freedom Broker analysts have maintained a "Buy" rating on aTyr Pharma (ATYR) shares with a $3.50 price target, suggesting a 536% upside from the current price. The key catalyst is the FDA's expected comments by the end of August on the protocol for a new Phase III study of efzofitimod for pulmonary sarcoidosis. Despite the potential, analysts note the investment remains high-risk, requiring a new Phase III trial and additional funding.
Life Sciences
- Published
- 17 Aug 2026 15:41
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 2.3% of the score · 11.1d old
- Duplicates
- 1 consolidated
#4—Not directional
simplywall.stDirect company coverageScored from headline
Here's Why We're A Bit Worried About aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation
- Published
- 14 Aug 2026 07:00
- News subject
- Balance sheet
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.5d old
- Duplicates
- 1 consolidated
#543Tone
vinanet.vnDirect company coverageScored from headline
ATYR Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares - Free Cash Flow Trends
- Published
- 14 Aug 2026 07:00
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 3.9% of the score · 14.5d old
- Duplicates
- 1 consolidated
#6—Not directional
MoomooDirect company coverageStored article
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1
Wells Fargo has reaffirmed its Hold rating for ATyr Pharma (ATYR.US) and maintained its price target at $1. This indicates that Wells Fargo believes the stock will perform in line with the market.
Financial MarketsLife Sciences
- Published
- 12 Aug 2026 16:14
- News subject
- Analyst action
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.1d old
- Duplicates
- 1 consolidated
#7—Not directional
MarketBeatDirect company coverageScored from headline
Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright
- Published
- 12 Aug 2026 10:40
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.3d old
- Duplicates
- 1 consolidated
#8—Not directional
BioXconomyDirect company coverageStored article
aTyr, Biogen, City name legal chiefs
Several biopharma companies, including aTyr Pharma, Biogen, City Therapeutics, CytomX Therapeutics, and Sanofi, have recently appointed new chief legal officers or general counsels. These appointments reflect a focus on bolstering legal and compliance functions as these companies advance their therapeutic programs and expand their operations. The new legal chiefs bring extensive experience in the biopharmaceutical and biotechnology industries to their respective roles.
FinanceLife Sciences
- Published
- 11 Aug 2026 20:14
- News subject
- Market update
- Why this score
- Business expansion
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.9d old
- Duplicates
- 1 consolidated
#9—Not directional
Investing.comDirect company coverageStored article
Why is aTyr Pharma stock gaining today?
aTyr Pharma's stock rose 1.8% in pre-open trading after announcing better-than-expected second-quarter results and a significant operational restructuring. The company reported a narrower loss per share, a 60% workforce reduction, and a focused pipeline on its lead candidate, efzofitimod, for interstitial lung disease. Investors are reacting positively to the extended cash runway, upcoming FDA feedback on a Phase 3 protocol, and completed enrollment in a Phase 2 study.
EarningsFinancial MarketsLife Sciences
- Published
- 10 Aug 2026 13:12
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.2d old
- Duplicates
- 1 consolidated
#1066Tone
nasdaq.comDirect company coverageStored article
ATyr Pharma Q2 Net Loss Narrows; Cuts Workforce By 60% To Advance Efzofitimod Into Phase 3
(RTTNews) - aTyr Pharma, Inc. (ATYR) announced second-quarter 2026 results and prioritised a corporate restructuring involving a 60% workforce reduction to advance its lead therapeutic candidate, Efzofitimod, in interstitial lung disease (ILD). aTyr's lead therapeutic candidate, efzofitimod, is a biologic immunomodulator in clinical development for the treatment of ILD, including pulmonary sarcoidosis and systemic sclerosis (SSc)-related ILD (SSc-ILD), that can cause inflammation and progressive fibrosis, or scarring, of the lungs. Second Quarter Results For the second quarter of 2026, net los
BIOTECHBiotechCLINICAL-TRIALSClinical TrialsEARNINGSEarnings
- Published
- 10 Aug 2026 07:45
- News subject
- Earnings
- Why this score
- Loss narrowed
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 43/100
- 30-day weight
- 4% of the score · 18.4d old
- Duplicates
- 2 consolidated
#11—Not directional
Fierce BiotechDirect company coverageStored article
aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug
aTyr Pharma is laying off 60% of its workforce to conserve resources for a second attempt at phase 3 success for its lung disease drug, efzofitimod. The company is awaiting FDA feedback on a new phase 3 study protocol after the drug missed its primary endpoint in a previous trial. The restructuring is expected to save $13 million annually and extend the cash runway into late 2028, though additional capital will still be needed.
EarningsLife Sciences
- Published
- 10 Aug 2026 06:12
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.5d old
- Duplicates
- 1 consolidated
#1223Tone
The National Law ReviewDirect company coverageStored article
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) Investors - Contact Levi & Korsinsky Before December 8, 2025
Levi & Korsinsky LLP has issued a securities lawsuit alert for investors of aTyr Pharma, Inc. (NASDAQ:ATYR). The alert concerns a class action lawsuit filed against aTyr Pharma, Inc. seeking to recover losses for shareholders who were adversely affected by alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage, prior to a negative study announcement that caused a significant stock price drop.
FinanceLife Sciences
- Published
- 10 Aug 2026 06:12
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 60/100
- 30-day weight
- 16.7% of the score · 18.5d old
- Duplicates
- 1 consolidated
#13—Not directional
MoomooDirect company coverageStored article
ATyr Pharma Announces Second Quarter 2026 Res
This article announces ATyr Pharma's second quarter 2026 results. The content is currently a placeholder and does not contain detailed financial information or a full report.
EarningsLife Sciences
- Published
- 08 Aug 2026 11:40
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.3d old
- Duplicates
- 4 consolidated
#1440Tone
TradingViewDirect company coverageStored article
aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary
aTyr Pharma (ATYR) reported a reduced net loss of $(10.3M) and an EPS of $(0.11) for Q2 2026, primarily due to lower research-and-development spending. The company plans to initiate a new global Phase 3 study for pulmonary sarcoidosis despite its EFZO-FIT trial missing its primary endpoint, and has implemented an operational restructuring including a 60% workforce reduction to conserve cash. aTyr Pharma is also advancing its preclinical candidate ATYR0101 and expanding its tRNA synthetase discovery platform.
EarningsLife Sciences
- Published
- 08 Aug 2026 02:40
- News subject
- Earnings
- Why this score
- Deteriorating financial comparison
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 2.8% of the score · 20.6d old
- Duplicates
- 1 consolidated
#1541Tone
TradingViewDirect company coverageStored article
aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD
aTYR Pharma reported a Q2 2026 net loss of $10.3 million and ended the quarter with $58.9 million in cash. The company is implementing a corporate restructuring, including a 60% workforce reduction, to conserve capital and focus on its lead candidate efzofitimod for interstitial lung disease (ILD). They have completed enrollment for a Phase 2 study in SSc-ILD and are awaiting FDA feedback on a Phase 3 protocol for pulmonary sarcoidosis.
EarningsFinanceLife Sciences
- Published
- 07 Aug 2026 23:40
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 2.1% of the score · 20.8d old
- Duplicates
- 2 consolidated
#1640Tone
GuruFocusDirect company coverageStored article
ATYR Looks 13.6% Overvalued on GF Value™ as It Restructures Amid Pulmonary Sarcoidosis Focus
aTyr Pharma Inc (NASDAQ: ATYR) announced its Q2 financial results and a major strategic restructuring, including a 60% workforce reduction, to prioritize its efzofitimod program for interstitial lung diseases. Despite an extremely high Price-to-Sales ratio of 255.7x and ongoing unprofitability, the company is preparing for FDA feedback on its Phase 3 pulmonary sarcoidosis study protocol. The stock is considered modestly overvalued by GuruFocus's GF Value™ and has a low GF Score™ of 18/100, though insider buying and stable guru ownership provide some positive signals.
EarningsFinanceFinancial MarketsLife Sciences
- Published
- 07 Aug 2026 23:39
- News subject
- Earnings
- Why this score
- Negative valuation view
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 2.7% of the score · 20.8d old
- Duplicates
- 1 consolidated
#1766Tone
MT NewswiresDirect company coverageStored article
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans
ATyr Pharma reported a narrower fiscal Q2 loss. The company also announced restructuring plans, with further details provided in the last three paragraphs of the article. Access to the full MT Newswires article requires a premium subscription.
EarningsLife Sciences
- Published
- 07 Aug 2026 20:39
- News subject
- Earnings
- Why this score
- Loss narrowed
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 42/100
- 30-day weight
- 2.8% of the score · 20.9d old
- Duplicates
- 1 consolidated
#18—Not directional
Associated PressDirect company coverageScored from headline
Atyr Pharma: Q2 Earnings Snapshot
- Published
- 07 Aug 2026 20:21
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.9d old
- Duplicates
- 1 consolidated
#1975Tone
scanx.tradeDirect company coverageScored from headline
aTyr Pharma Q2 Results: EPS of $(0.11) beats estimates
- Published
- 07 Aug 2026 07:00
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 52/100
- 30-day weight
- 2.8% of the score · 21.5d old
- Duplicates
- 1 consolidated
#20—Not directional
MarketBeatDirect company coverageScored from headline
aTyr Pharma (ATYR) Earnings Date and Reports 2026
- Published
- 07 Aug 2026 07:00
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.5d old
- Duplicates
- 1 consolidated
#2120Tone
The National Law ReviewDirect company coverageStored article
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 - Contact Levi & Korsinsky
A class action securities lawsuit has been filed against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made false and misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage. The stock price dropped significantly after aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to an 83.2% decline in one day.
FinanceFinancial MarketsLife Sciences
- Published
- 07 Aug 2026 04:11
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 62/100
- 30-day weight
- 13.3% of the score · 21.6d old
- Duplicates
- 3 consolidated
#22—Not directional
Stock TitanDirect company coverageStored article
FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership
FMR LLC and Abigail P. Johnson have reported a 2.5% passive ownership stake in ATYR Pharma Inc. This disclosure, made via an amended Schedule 13G, indicates that FMR LLC beneficially owns 2,471,418 shares, with sole voting power over 2,464,141 shares and sole dispositive power over all 2,471,418 shares. Abigail P. Johnson also holds sole dispositive power over the same number of shares, reflecting her control over FMR-related entities.
FinanceLife Sciences
- Published
- 06 Aug 2026 14:10
- News subject
- Deals and strategy
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.2d old
- Duplicates
- 1 consolidated
#2334Tone
The National Law ReviewDirect company coverageStored article
Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025 - Contact Levi & Korsinsky
Levi & Korsinsky LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the efficacy of its drug Efzofitimod. The stock price dropped significantly after the company announced that a key study did not meet its primary endpoint, causing an 83.2% decline in one day.
FinanceLife Sciences
- Published
- 05 Aug 2026 11:43
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 44/100
- 30-day weight
- 7.2% of the score · 23.3d old
- Duplicates
- 2 consolidated
#2460Tone
TradingKeyDirect company coverageScored from headline
LIFE|aTyr Pharma Ord Shs|Price:22.810|Chg%:+2.390
- Published
- 04 Aug 2026 09:45
- News subject
- Market update
- Why this score
- Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- <0.1% of the score · 24.3d old
- Duplicates
- 1 consolidated
#2525Tone
The National Law ReviewDirect company coverageStored article
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities Violations – Contact Levi & Korsinsky Today
A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to reduce steroid usage. This news follows a significant 83.2% stock price drop on September 15, 2025, after aTyr announced its EFZO-FIT study did not meet its primary endpoint.
FinanceFinancial MarketsLife Sciences
- Published
- 04 Aug 2026 02:09
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 55/100
- 30-day weight
- 8.7% of the score · 24.7d old
- Duplicates
- 1 consolidated
#26—Not directional
marketscreener.comDirect company coverageStored article
Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn
MarketScreener has withdrawn alerts regarding Ethos Technologies' Q2 results that were erroneously attributed to aTyr Pharma, Inc. The original publication was made on August 3, 2026, at 04:48 pm EDT by Reuters. This correction highlights a data misattribution concerning financial reporting.
EarningsLife Sciences
- Published
- 03 Aug 2026 21:09
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.9d old
- Duplicates
- 1 consolidated
#2741Tone
TradingViewDirect company coverageStored article
aTyr Pharma Inc expected to post a loss of 12 cents a share - Earnings Preview
aTyr Pharma Inc is projected to report a loss of 12 cents per share, according to an earnings preview. This information is sourced from Refinitiv and was published by Reuters. The full article is available on TradingView, which aggregates news from various sources.
EarningsLife Sciences
- Published
- 03 Aug 2026 11:43
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 1.1% of the score · 25.3d old
- Duplicates
- 1 consolidated
#2843Tone
VinanetDirect company coverageScored from headline
ATYR Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares Up 1.19% - Earnings Surprise Score
- Published
- 03 Aug 2026 07:00
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 31/100
- 30-day weight
- 0.8% of the score · 25.5d old
- Duplicates
- 1 consolidated
#29—Not directional
TradingViewDirect company coverageScored from headlineSource lookup
aTyr Pharma, Inc. Revenue Breakdown – NASDAQ:ATYR
- Published
- 02 Aug 2026 07:24
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.4d old
- Duplicates
- 1 consolidated
#30—Not directional
vinanet.vnDirect company coverageScored from headline
aTyr Pharma (ATYR) Rises 1.25% as Shares Defend Key $0.47 Support Level - Trading Ideas
- Published
- 01 Aug 2026 07:00
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.5d old
- Duplicates
- 1 consolidated
Earlier company news
ATYR news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 31 older ATYR headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to ATYR, but the headline and available text are not mainly about aTyr Pharma, Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ATYR sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.